BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33014825)

  • 1. Aberrant
    Huang S; Huang Z; Chen P; Feng C
    Front Oncol; 2020; 10():1648. PubMed ID: 33014825
    [No Abstract]   [Full Text] [Related]  

  • 2. Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia.
    Huang S; Huang Z; Ma C; Luo L; Li YF; Wu YL; Ren Y; Feng C
    Ann Transl Med; 2020 Mar; 8(6):345. PubMed ID: 32355789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
    Shi J; Fu H; Jia Z; He K; Fu L; Wang W
    EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
    He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
    Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
    Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
    Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
    Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
    PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia.
    Fu L; Fu H; Zhou L; Xu K; Pang Y; Hu K; Wang J; Tian L; Liu Y; Wang J; Jing H; Huang W; Ke X; Shi J
    Sci Rep; 2016 Sep; 6():34546. PubMed ID: 27686215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
    Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
    Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
    Metzeler KH; Becker H; Maharry K; Radmacher MD; Kohlschmidt J; Mrózek K; Nicolet D; Whitman SP; Wu YZ; Schwind S; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    Blood; 2011 Dec; 118(26):6920-9. PubMed ID: 22031865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
    Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
    Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
    Cao L; Zhang W; Liu X; Yang P; Wang J; Hu K; Zhang X; Liu W; He X; Jing H; Yuan X
    Sci Rep; 2019 Nov; 9(1):16991. PubMed ID: 31740742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
    Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Quan L; Qian T; Zeng T; Si C; Huang W; Chen J; Pang Y; Ye X; Shi J; Fu L
    J Cell Mol Med; 2020 Jan; 24(1):1067-1075. PubMed ID: 31755224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel.
    Šestáková Š; Cerovská E; Šálek C; Kundrát D; Ježíšková I; Folta A; Mayer J; Ráčil Z; Cetkovský P; Remešová H
    Clin Epigenetics; 2022 Feb; 14(1):22. PubMed ID: 35148810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher Expression of
    Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
    Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.